Published in Clin Infect Dis on September 20, 2005
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2015) 4.07
Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat Genet (2010) 3.65
Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol (2007) 2.29
Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev (2011) 2.22
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest (2013) 2.00
Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol (2007) 1.99
Organ-specific innate immune responses in a mouse model of invasive candidiasis. J Innate Immun (2010) 1.94
Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis (2012) 1.91
Candida infections of the genitourinary tract. Clin Microbiol Rev (2010) 1.90
Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis (2006) 1.89
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog (2009) 1.76
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One (2011) 1.73
Passage through the mammalian gut triggers a phenotypic switch that promotes Candida albicans commensalism. Nat Genet (2013) 1.63
PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog (2010) 1.63
Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol (2006) 1.63
Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog (2011) 1.53
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol (2008) 1.51
Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog (2012) 1.49
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med (2014) 1.45
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol (2008) 1.36
Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis (2010) 1.36
Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care (2011) 1.35
Active surveillance for candidemia, Australia. Emerg Infect Dis (2006) 1.30
Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis (2010) 1.29
Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One (2012) 1.27
Saccharomyces cerevisiae: population divergence and resistance to oxidative stress in clinical, domesticated and wild isolates. PLoS One (2009) 1.26
Heterologous expression of Candida albicans cell wall-associated adhesins in Saccharomyces cerevisiae Reveals differential specificities in adherence and biofilm formation and in binding oral Streptococcus gordonii. Eukaryot Cell (2010) 1.24
Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol (2011) 1.23
Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis (2010) 1.18
Trehalose pathway as an antifungal target. Virulence (2016) 1.17
Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS One (2007) 1.13
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother (2012) 1.11
Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol (2008) 1.11
Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog (2012) 1.10
Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol (2013) 1.10
Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol (2008) 1.10
Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J (2009) 1.09
Mapping the Hsp90 genetic interaction network in Candida albicans reveals environmental contingency and rewired circuitry. PLoS Genet (2012) 1.07
Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis (2014) 1.07
New insights into innate immune control of systemic candidiasis. Med Mycol (2014) 1.05
Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients. Crit Care (2008) 1.04
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms. Antimicrob Agents Chemother (2008) 1.03
Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov (2013) 1.03
β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One (2012) 1.00
Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol (2011) 1.00
Development of a high-throughput Candida albicans biofilm chip. PLoS One (2011) 1.00
Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol (2013) 1.00
Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med (2014) 0.99
Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry. Eur J Clin Microbiol Infect Dis (2013) 0.98
Candidemia is costly--plain and simple. Clin Infect Dis (2005) 0.97
Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int (2013) 0.97
Risk prediction for invasive candidiasis. Indian J Crit Care Med (2014) 0.95
Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control (2010) 0.95
Invasive fungal disease in PICU: epidemiology and risk factors. Ann Intensive Care (2012) 0.94
Dectin-1 is not required for controlling Candida albicans colonization of the gastrointestinal tract. Infect Immun (2012) 0.93
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care (2009) 0.91
Prevalence of fungal infections using National Health Insurance data from 2009-2013, South Korea. Epidemiol Health (2014) 0.91
Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob Agents Chemother (2011) 0.91
Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur J Clin Microbiol Infect Dis (2007) 0.91
Candida albicans specializations for iron homeostasis: from commensalism to virulence. Curr Opin Microbiol (2013) 0.90
Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit Care (2010) 0.90
A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis (2008) 0.90
Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis (2008) 0.90
Evolutionary dynamics of Candida albicans during in vitro evolution. Eukaryot Cell (2011) 0.90
Prediction of pediatric death in the year after hospitalization: a population-level retrospective cohort study. J Palliat Med (2009) 0.89
Altered dynamics of Candida albicans phagocytosis by macrophages and PMNs when both phagocyte subsets are present. MBio (2013) 0.89
Candida isolation in patients hospitalized on a surgical ward: significance and mortality-related factors. World J Surg (2009) 0.88
Trends in nosocomial bloodstream infections in a burn intensive care unit: an eight-year survey. Ann Burns Fire Disasters (2010) 0.88
Lipolytic enzymes involved in the virulence of human pathogenic fungi. Mycobiology (2013) 0.88
Candidemia in children after complex congenital heart defects surgery treated with caspofungin--our own experience and a review of literature. Med Sci Monit (2011) 0.87
Mortality in patients with early- or late-onset candidaemia. J Antimicrob Chemother (2012) 0.87
Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One (2012) 0.86
Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents (2012) 0.86
Incidence and predictors of invasive candidiasis associated with candidaemia in children. Mycoses (2011) 0.85
Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother (2012) 0.85
Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. Pediatr Rep (2012) 0.85
Shuttle vectors for facile gap repair cloning and integration into a neutral locus in Candida albicans. Microbiology (2013) 0.84
Identification of Candida glabrata genes involved in pH modulation and modification of the phagosomal environment in macrophages. PLoS One (2014) 0.84
Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study. J Nanobiotechnology (2015) 0.84
Functional regions of Candida albicans hyphal cell wall protein Als3 that determine interaction with the oral bacterium Streptococcus gordonii. Microbiology (2014) 0.84
Synthetic multivalent antifungal peptides effective against fungi. PLoS One (2014) 0.83
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature. Eur J Med Res (2011) 0.83
Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil. Mem Inst Oswaldo Cruz (2013) 0.83
Oxidative stress survival in a clinical Saccharomyces cerevisiae isolate is influenced by a major quantitative trait nucleotide. Genetics (2011) 0.83
Superantigen-like effects of a Candida albicans polypeptide. J Infect Dis (2008) 0.83
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. BMC Infect Dis (2006) 0.82
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis (2011) 0.82
Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol (2010) 0.82
Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections. Am J Infect Control (2010) 0.82
Hsp90 is involved in apoptosis of Candida albicans by regulating the calcineurin-caspase apoptotic pathway. PLoS One (2012) 0.82
Effect of beta-1,6-glucan inhibitors on the invasion process of Candida albicans: potential mechanism of their in vivo efficacy. Antimicrob Agents Chemother (2009) 0.82
The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections. Eur J Clin Microbiol Infect Dis (2015) 0.81
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res (2011) 0.81
Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis (2009) 0.81
Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. BMC Pharmacol Toxicol (2014) 0.81
Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of Candida spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents. J Clin Microbiol (2011) 0.80
Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. BMC Infect Dis (2012) 0.80
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
The continuing unethical conduct of underpowered clinical trials. JAMA (2002) 10.34
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (2013) 9.01
Pediatric do-not-attempt-resuscitation orders and public schools: a national assessment of policies and laws. Am J Bioeth (2005) 8.45
SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med (2013) 8.21
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med (2007) 4.56
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med (2007) 4.26
Children with complex chronic conditions in inpatient hospital settings in the United States. Pediatrics (2010) 3.84
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics (2002) 3.22
SUPPORT and the Ethics of Study Implementation: Lessons for Comparative Effectiveness Research from the Trial of Oxygen Therapy for Premature Babies. Hastings Cent Rep (2014) 3.15
Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol (2005) 3.11
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis (2004) 3.10
Meta-analysis of the effect of an essential oil-containing mouthrinse on gingivitis and plaque. J Am Dent Assoc (2015) 3.07
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol (2005) 3.06
Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage (2003) 3.05
Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis (2004) 2.98
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis (2004) 2.89
Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med (2005) 2.79
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis (2003) 2.73
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials (2009) 2.49
Empirical assessment of whether moderate payments are undue or unjust inducements for participation in clinical trials. Arch Intern Med (2004) 2.49
Hospital utilization and characteristics of patients experiencing recurrent readmissions within children's hospitals. JAMA (2011) 2.45
Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics (2003) 2.38
Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics (2009) 2.35
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med (2005) 2.34
Randomized trial of 5 dollars versus 10 dollars monetary incentives, envelope size, and candy to increase physician response rates to mailed questionnaires. Med Care (2002) 2.30
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J (2007) 2.25
The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol (2002) 2.21
National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc (2002) 2.20
Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol (2007) 2.19
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J (2004) 2.08
Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation (2003) 2.07
Use of ClinicalTrials.gov to estimate condition-specific nocebo effects and other factors affecting outcomes of analgesic trials. J Pain (2013) 2.06
Human rhinoviruses. Clin Microbiol Rev (2013) 2.05
Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics (2007) 2.05
Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis (2006) 2.02
Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy. Arch Intern Med (2003) 2.02
Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol (2004) 2.02
Placement stability and mental health costs for children in foster care. Pediatrics (2004) 2.01
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97
The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis (2014) 1.94
A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemiol Biomarkers Prev (2006) 1.93
Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency. Am Heart J (2003) 1.89
Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis (2008) 1.88
Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics (2010) 1.86
Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics (2003) 1.86
Socioeconomic disparities in the use and success of fertility treatments: analysis of data from a prospective cohort in the United States. Fertil Steril (2011) 1.85
Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol (2013) 1.83
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother (2002) 1.79
The OHRP and SUPPORT. N Engl J Med (2013) 1.78
Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion (2002) 1.77
The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol (2004) 1.76
Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst (2005) 1.75
Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol (2005) 1.74
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2002) 1.72
Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol (2007) 1.70
An international survey indicated that unpublished systematic reviews exist. J Clin Epidemiol (2009) 1.70
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Emerging and less common fungal pathogens. Infect Dis Clin North Am (2002) 1.68
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs (2004) 1.67
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J (2010) 1.66
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis (2004) 1.64
Improving the care of children with advanced cancer by using an electronic patient-reported feedback intervention: results from the PediQUEST randomized controlled trial. J Clin Oncol (2014) 1.63
Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomarkers Prev (2007) 1.62
Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer (2002) 1.62
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol (2005) 1.61
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother (2002) 1.61
Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother (2005) 1.59
Variation in receipt of opioids by pediatric oncology patients who died in children's hospitals. Pediatr Blood Cancer (2009) 1.56
A novel application of 1H magnetic resonance spectroscopy: non-invasive identification of spermatogenesis in men with non-obstructive azoospermia. Hum Reprod (2010) 1.56
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother (2006) 1.55
Parental decision-making preferences in the pediatric intensive care unit. Crit Care Med (2012) 1.55
Factors affecting decisions to seek treatment for sick children in Kerala, India. Soc Sci Med (2003) 1.54
Racial differences in vasectomy utilization in the United States: data from the national survey of family growth. Urology (2009) 1.53
Pediatric hospital discharge interventions to reduce subsequent utilization: a systematic review. J Hosp Med (2013) 1.50